This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imsidolimab in adolescent and adult subjects with acne vulgaris (AV). This study also will characterize the pharmacokinetic (PK) profile of Imsidolimab and explore the immune response to Imsidolimab in subjects with AV.
Efficacy and Safety of Imsidolimab in Subjects with Acne Vulgaris